Dr. Reddy’s Laboratories announces the launch of Ertapenem for injection on the US market

Dr. Reddy’s Laboratories announces the launch of Ertapenem for injection on the US market

*IQVIA Retail and Non-Retail MAT March 2021 INVANZ is a trademark of Merck and Co., Inc RDY-0421-338

Dr. Reddy’s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton. The INVANZ brand and generic market had U.S. sales of approximately $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health*.

Please click here for full prescribing information: https://www.drreddys.com/media/986993/100962_ertapenem_for_injection_leaflet-original.pdf “We are delighted about this collaboration, as it brings together Dr. Reddy’s experienced marketing and distribution capabilities and Gland Pharma’s robust development and manufacturing capabilities. Gland Pharma has an exclusive API supply arrangement for this product and a dedicated manufacturing facility in Hyderabad for Ertapenem Injection. With the launch of this product we see increased capacity utilization of this dedicated Penem facility,” says Mr. Srinivas Sadu, MD and CEO of Gland Pharma Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006310/en/ Source Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein.”

About Gland Pharma Limited (BSE: 543245, NSE: GLAND): Gland Pharma was established in 1978 in Hyderabad, has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

The News Highlights

  • Dr. Reddy’s Laboratories announces the launch of Ertapenem for injection on the US market
  • Check the latest Gaming news updates and information about games.
  • Please share this news with your friends and family to support us your one share helps us a lot.
  • Follow us on Facebook and Twitter, for similar updates.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Crypto Shadow Banking explained and why 12% of earnings are common

Should pandemic recovery money finance sewer infrastructure?

“We could use a small portion to build a beautiful self-sustaining community garden network,” Inyang suggested. Dougherty County has the highest food ...
City Market asks city for financial aid at Thursday meeting – WISH-TV |  Indianapolis News |  Indian Weather

City Market asks city for financial aid at Thursday meeting – WISH-TV | Indianapolis News | Indian Weather

Ryan Evans, owner of His & Hers Boutique agreed, adding only about half of the vendors are still in business. “With all of the construction and the fact a ...
Company that owns Mesa Mall is in bankruptcy proceedings |  The business

Company that owns Mesa Mall is in bankruptcy proceedings | The business

It filed in the U.S. Bankruptcy Court for the Southern District of Texas in Houston, according to the release. It has secured $100 million in money for ...
Experts discuss how schools act as a community health center – news

Experts discuss how schools act as a community health center – news

The panelists included Sara Lurie, CEO of the CMH Authority of Clinton-Eaton-Ingham counties, Rachel VanDenBrink, president-elect of Michigan Association of ...
A better way to pay for health care

A better way to pay for health care

The political debate also tends to conflate health care technology and health care. There has been deserved praise about how our collective ingenuity produced ...
Candy Store in Manassas Grows  News to Help Support Others |  WDVM25 and DCW50

Candy Store in Manassas Grows News to Help Support Others | WDVM25 and DCW50

Rouse said her food truck is here to stay and will continue to serve the community that has helped her along the way. “We don’t get a lot of donations now ...
Even with California’s reopening, many corporate customers keep the masks –  NewsSan Francisco

Even with California’s reopening, many corporate customers keep the masks – NewsSan Francisco

Throughout the pandemic, mandatory mask requirements became a point of contention with many expressing frustration with what they felt were overreaching public ...
Buyer’s Guide to IBM Smart  News Automation

Buyer’s Guide to IBM Smart News Automation

Get a full set of modular, integrated capabilities to help you start and scale your automation projects quickly. There are a lot of automation technologies out ...
Former DC board employee loses health insurance after DCHR delay

Former DC board employee loses health insurance after DCHR delay

“We require specific interpretation of regulations governing the District’s responsibility,” the DCHR rep wrote in an email. “Specifically as it corresponds to ...
Razer launched most exciting gadgets recently

Razer launched most exciting gadgets recently

Razer Blade 14 is offered in three configurations. The base model comes with the Nvidia GeForce RTX 3060 GPU and is priced at $1,799 (roughly Rs. 1.31 ...
Show next
Compsmag - Latest News from tech, business and health
Logo